Compound 211
Identifiers
- Canonical SMILES:
CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1nc2cc(ccc2o1)C(O)=O)c1cc(Cl)cc(Cl)c1
- IUPAC name:
2-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl]-1,3-benzoxazole-5-carboxylic acid
- InChi:
InChI=1S/C28H19Cl2N5O5/c1-33-27(39)35(20-10-18(29)9-19(30)11-20)25(38)28(33)14-34(13-21(28)16-4-2-15(12-31)3-5-16)26-32-22-8-17(24(36)37)6-7-23(22)40-26/h2-11,21H,13-14H2,1H3,(H,36,37)/t21-,28+/m0/s1
- InChiKey:
ADBMUKYDRHZIQJ-RBTNQOKQSA-N
External links
46221191 |
CHEMBL1094127 |
24678944 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
LFA / ICAM | 8.40 | immune system disease | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 575.08 g/mol | |||
HBA | 10 | |||
HBD | 1 | |||
HBA + HBD | 11 | |||
AlogP | 5.11 | |||
TPSA | 130.98 | |||
RB | 4 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5187 | Suvorexant | DB09034 | |
0.4943 | Degarelix | DB06699 | |
0.4837 | N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE | DB07839 | |
0.4361 | ALK-4290 | DB15269 | |
0.4360 | BMS-564929 | DB07286 | |
0.4319 | Ubrogepant | DB15328 | |
0.4316 | Alatrofloxacin | DB09335 | |
0.4296 | Ivosidenib | DB14568 | |
0.4281 | Bremelanotide | DB11653 | |
0.4269 | Telinavir | DB12178 | |
0.4212 | SAR-405838 | DB12541 | |
0.4209 | Olcegepant | DB04869 | |
0.4173 | LTX-109 | DB12711 | |
0.4170 | Bombesin | DB11724 | |
0.4137 | Triptorelin | DB06825 |